9-Me-BC

Also known as: 9-Methyl-beta-carboline, 9-MBC, 9-methylnorharman, 9-methylpyrido[3,4-b]indole

Evidence: Preclinical

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

Overview

9-Methyl-beta-carboline, a small-molecule alkaloid shown in rodent studies to promote dopamine neuron survival and improve learning and memory.

9-Methyl-beta-carboline is a small-molecule pyridoindole alkaloid, not a peptide. Most beta-carbolines are studied as neurotoxins; this one is the exception. In primary mouse mesencephalic culture it raised the number of differentiated dopaminergic neurons, cut caspase-3 activity and induced dopaminergic transcription factors (Hamann et al., 2008), and it protected and partly regenerated those neurons after lipopolysaccharide or rotenone injury while suppressing microglial proliferation (Polanski et al., 2010). Given into the cerebral ventricle of rats for 14 days after MPP+ lesioning, it restored striatal dopamine and nigral cell counts (Wernicke et al., 2010). Ten days of treatment improved radial-maze learning in rats alongside higher hippocampal dopamine and more dendritic spines (Gruss et al., 2012). It inhibits monoamine oxidase A and B (Keller et al., 2020). No human study exists.

Benefits

Dopaminergic neuron support and improved learning/memory in rodent models; studied for neuroprotection

Dosing reference

Research dose: 10 to 30 mg daily (vendor/community range, no published human dose; rat in vivo work used intracerebroventricular delivery)
Range: 10000 to 30000 mcg, 1x daily

Oral use is community convention; no human study has administered this compound. The restorative rat study delivered it into the left cerebral ventricle for 14 days (Wernicke et al., 2010) and the cognitive study dosed rats for 10 days (Gruss et al., 2012). 9-Methyl-beta-carbolines are efficient photosensitisers and damage DNA under UVA in vitro, generating oxidised purines and pyrimidine dimers (Vignoni et al., 2013). Monoamine oxidase A inhibition at about 1 micromolar is a measured property (Keller et al., 2020), which is the basis for caution with serotonergic drugs and tyramine. N/A-by-design: oral, so reconstitution fields are null.

Mechanism

9-Methyl-beta-carboline is a heterocyclic pyridoindole alkaloid (not a peptide). In primary dopaminergic culture it raised tyrosine hydroxylase expression in existing dopa-decarboxylase-positive neurons and induced transcription factors tied to dopaminergic differentiation (Hamann et al., 2008). It also protects and regenerates those neurons after toxin exposure, suppresses microglial proliferation and lowers alpha-synuclein (Polanski et al., 2010). In rats it raised complex I activity and induced BDNF, CDNF, CBLN1 and CNTF transcripts (Wernicke et al., 2010). Astrocytes mediate part of the effect through organic cation transport and PI3K signalling, and the compound inhibits monoamine oxidase, IC50 about 1 micromolar for MAO-A and 15.5 micromolar for MAO-B (Keller et al., 2020). Photoexcited 9-methyl-beta-carbolines damage DNA in vitro under UVA (Vignoni et al., 2013).

Evidence

Preclinical: animal or in vitro data only

Raised the number of differentiated dopaminergic neurons and lowered caspase-3 activity in primary mouse mesencephalic culture (Hamann et al., 2008)
Protected dopaminergic neurons against lipopolysaccharide and 2,9-dimethyl-beta-carbolinium toxicity, regenerated them after chronic rotenone, and suppressed toxin-induced microglial proliferation (Polanski et al., 2010)
Fourteen days of intracerebroventricular dosing in MPP+-lesioned rats restored striatal dopamine and nigral tyrosine hydroxylase cell counts, with about 80% higher complex I activity (Wernicke et al., 2010)
Ten days of treatment improved radial-maze spatial learning in rats, with higher hippocampal dopamine and greater dendritic and synaptic density; five days did not (Gruss et al., 2012)
Inhibits monoamine oxidase A at about 1 micromolar and MAO-B at 15.5 micromolar, and stimulates neurotrophic factor expression in astrocytes through PI3K (Keller et al., 2020)
Human-trial status: none. No clinical trial, no human pharmacokinetics and no human safety data; all work is rodent or cell culture, and the in vivo rat studies used intracerebroventricular delivery

References

Side effects

No human safety data; effects unknown beyond animal studies in rodents. Beta-carbolines inhibit monoamine oxidase at higher concentrations, so combining with SSRIs, MAOIs, stimulants, or tyramine-rich foods poses serotonin syndrome and hypertensive crisis risk. Liver enzyme changes in rodent work make hepatic monitoring prudent.

Storage

Storage: Room temperature, away from light
Lyophilized: 12+ months

Pharmacology

Half-life: Not established in any species; no pharmacokinetic study published
Bioavailability: Not measured. Beta-carbolines occur endogenously and in food, and 9-methyl-beta-carboline has been detected in brain and cerebrospinal fluid in the broader literature, but no oral bioavailability or brain-uptake figure exists for the administered compound (Hamann et al., 2008; Keller et al., 2020).
Molecular weight: 182.22 Da
Sequence: N/A - small molecule pyridoindole alkaloid, 9-methylpyrido[3,4-b]indole (PubChem CID 164979)